Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
23.54% 24.20% 22.54% 22.31%

+8 more TTM periods

ROA
17.12% 17.58% 16.41% 15.60%
ROIC
24.09% 24.15% 21.63% 22.62%
Return on Tangible Assets
42.89% 45.87% 44.62% 48.87%
Average Days of Receivables
61.89 59.63 62.43 60.60
Free Cash Flow per Share
14.96 14.60 12.49 13.06
Free Cash Flow
3,796.10 3,710.30 3,193.80 3,337.20
Capital Expenditures
(496.80) (530.30) (437.60) (380.80)
Piotroski F-Score
4.00 7.00 7.00 7.00
Other line items
Cash ROIC
15.28% 15.94% 14.37% 15.75%
Accounts Receivable Turnover
6.25 6.43 6.55 6.34
Accounts Payable Turnover
4.04 3.60 3.78 3.94
Inventory Turnover
1.08 1.08 1.14 1.19
Average Days of Payables
88.93 106.24 102.05 95.36
Days of Inventory on Hand
365.48 383.59 372.85 369.11
Tax Rate
(0.16) (0.16) (0.15) (0.17)
Research and Development Expense of Revenue
31.04% 31.85% 32.58% 33.56%
Selling, General and Administrative Expense of Revenue
15.95% 15.14% 14.61% 14.02%
Share Based Compensation of Revenue
5.47% 5.62% 5.72% 5.94%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.97 0.98 0.92 1.01
Depreciation/Fixed assets
0.13 0.14 0.14 0.14
Capex/Depreciation
(2.24) (2.44) (2.09) (1.90)
Revenue per Share
49.61 48.08 46.94 45.87
Operating CF per Share
16.92 16.69 14.20 14.55
Capex per Share
(1.96) (2.09) (1.71) (1.49)
Capex to Sales
0.04 0.04 0.04 0.03
Net Profit Margin
35.00% 35.51% 32.94% 31.35%

Fold the line items

Columns are period end dates